Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 11Completed 8Terminated 5Recruiting 5Withdrawn 1Not yet recruiting 1Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Plasma cell 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Multiple Myeloma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × erdafitinib × Clear all
NCT04754425 2026-02-06

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled
Genitourinary

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

University of Washington

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT03827850 2023-06-09

FIND

Lung Cancer Group Cologne

Phase 2 Terminated
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05052372 2022-12-22

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

xCures

Terminated
2 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02952573 2020-09-17

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

University Health Network, Toronto

Phase 2 Terminated
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡